FAP, April 23, Baili Tianheng announced that BL-M11D1 (CD33-ADC), an innovative biological drug independently developed by the company, received the "Drug Clinical trial approval notice" issued by the State Drug Administration on the 18th of this month, agreeing to carry out clinical trials of relapsed or refractory acute myeloid leukemia. In addition, the company's independent research and development of innovative biological drug BL-B01D1-related combination drug "BL-B01D1 combined with oxitinib mesylate", on the 20th of this month, received the "Drug Clinical trial approval notice" issued by the State Drug Administration, agreeing to carry out the clinical trial of this product combined with oxitinib mesylate tablets in the treatment of locally advanced or metastatic non-small cell lung cancer patients with EGFR mutation.